BRAF and ameloblastoma: Notably, ameloblastoma cell lines harboring BRAF p.V600E mutation seem to be sensitive to vemurafenib, i.e., a BRAF small molecule inhibitor, which inhibited cell proliferation and MAPK/ERK activation [51, 52].